Sigma-1 receptor agonist combination
This page covers all Sigma-1 receptor agonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Sigma-1 receptor.
Targets
Marketed (1)
- Nuedexta (20/10) · St. Joseph's Hospital and Medical Center, Phoenix · Neurology
Nuedexta combines dextromethorphan (a sigma-1 receptor agonist) and quinidine (a CYP2D6 inhibitor) to reduce involuntary emotional expression disorder (pseudobulbar affect) by modulating emotional pathways in the brain.
Patent intelligence
- sigma 1 receptor agonist combination patent landscape — aggregated cliff calendar, attackable patents, originator estates